异动解读 | 德纳维制药盘中大涨9.04%,超预期季度业绩提振投资者信心

异动解读
Aug 08

周五盘中,德纳维制药(DVAX)股价大涨9.04%,引发市场广泛关注。这一显著涨幅主要源于公司发布的超预期第二季度财报,展现出强劲的业务增长势头。

根据公司最新发布的财报显示,截至2025年6月30日的第二季度,德纳维制药调整后每股收益达到14美分,不仅显著高于去年同期的8美分,还超过了分析师平均预期的11美分。公司季度营收同比增长29.3%,达到9544万美元,同样超出市场预期的8666万美元。这一亮眼业绩无疑增强了投资者对公司未来发展的信心。

值得注意的是,尽管德纳维制药今年以来股价累计下跌12.4%,但分析师对公司前景保持乐观态度。目前,华尔街分析师对该公司股票的平均评级为"买入",12个月目标价中位数为25.00美元,较当前股价有显著上涨空间。这表明市场普遍看好公司的长期发展潜力,而此次超预期的季度业绩无疑为股价提供了强劲支撑。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10